Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNI ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2023 were $291 million, a decrease of $7 million or down 2% from the prior quarter and a decrease of $28 million or down 9% year-over-year [57] - Non-GAAP EBITDA for Q1 2023 was $27 million, an increase of $1 million compared to the previous quarter but a decrease of $24 million year-over-year [66] - Non-GAAP earnings per share for Q1 2023 were $0.39, compared to $0.33 in the prior quarter and $0.83 in the same period last year [66] Business Line Data and Key Metrics Changes - Services revenues for Q1 2023 were $105 million, an increase of 12% over Q1 2022, indicating successful digital transformation efforts [58] - The specialty pharmacy service continues to gain traction, with new partnerships established in Q1 2023, including a major Illinois health system and a Texas-based medical center [46] Market Data and Key Metrics Changes - The healthcare industry is facing ongoing labor constraints and capital budget challenges, which are expected to persist throughout 2023 [11] - Despite these challenges, there is a noted stabilization in the market, with health systems increasingly recognizing the need for automated medication management solutions [35][39] Company Strategy and Development Direction - The company is focused on integrating recent acquisitions to enhance its advanced services offerings, including ReCept, FDS Amplicare, and MarkeTouch Media [37] - A strategic alliance with Long Island University was announced to open the Center for Innovative Medication Management, aimed at fostering pharmacy education and technology [48][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic uncertainties while executing its growth strategy [18][55] - The company anticipates a sequential revenue growth from the first half to the second half of 2023, supported by a healthy backlog [70] Other Important Information - The company is undergoing a search for a new CFO as the current CFO is set to step down [28] - The company published its 2022 ESG report, highlighting efforts to protect patient data and foster a culture of inclusivity [27] Q&A Session Summary Question: Can you provide updates on the Specialty Services pipeline and the 340B opportunity? - Management indicated strong growth in the pipeline for Specialty Services, particularly in response to health systems' needs for specialty pharmacy operations [12] Question: What is the expectation for inflation trends in 2023? - Management expects pricing impacts to exceed inflation, with sufficient semiconductor inventory to cover most of the year [64][65] Question: How is the backlog trending as we approach midyear? - Management noted that the backlog remains healthy, with significant revenue expected to come from it [71] Question: What part of EnlivenHealth is resonating most with retail pharmacies? - The focus is on patient engagement and chronic care management, with retail pharmacies seeking better solutions for revenue cycle management [52][53] Question: What is the outlook for the point-of-care XT product line? - Management expects a stable continuation of the upgrade cycle for the XT series, despite some choppiness during the pandemic [97]

Omnicell, Inc. (NASDAQ:OMCL) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Founder, Chairman, President and CEO Scott Seidelmann - Executive Vice President and CCO Peter Kuipers - Executive Vice President and CFO Conference Call Participants Stan Berenshteyn - Wells Fargo Securities Matt Hewitt - Craig-Hallum Capital Group Scott Schoenhaus - KeyBanc Jessica Tassan - Piper Sandler Bill Sutherland ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICELL, INC. (Exact name of regis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) 2625 Augustine Drive, Suite 301 Santa Clara, CA 95054 (Address of registrant's principal executive offices, including zip code) (650) 251-6100 (R ...

Omnicell, Inc. (NASDAQ:OMCL) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Chairman, President, Chief Executive Officer, and Founder Scott Seidelmann - Executive Vice President and Chief Commercial Officer Peter Kuipers - Executive Vice President and Chief Financial Officer Conference Call Participants Stan Berenshteyn - Wells Fargo Securities Jessica Tassan - Piper Sandler Allen Lutz - Bank of Am ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICELL ...

Omnicell, Inc. (NASDAQ:OMCL) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Kathleen Nemeth - Senior Vice President, Investor Relations Randall Lipps - Chairman, President, Chief Executive Officer, and Founder Scott Seidelmann - Executive Vice President and Chief Commercial Officer Peter Kuipers - Executive Vice President and Chief Financial Officer Conference Call Participants Joy Zeng - SVB Securities Stan Berenshteyn - Wells Fargo Jessica Tassan - Piper Sandler Lucas Bar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNICEL ...

Omnicell, Inc. (NASDAQ:OMCL) Q1 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Randall Lipps - Chairman, President, Chief Executive Officer Peter Kuipers - Executive Vice President and Chief Financial Officer Scott Seidelmann - Executive Vice President, Chief Commercial Officer Kathleen Nemeth - Senior Vice President, Investor Relations Conference Call Participants Scott Schoenhaus - Stephens Jessica Tassan - Piper Sandler Anne Samuel - JP Morgan Chase Matt Hewitt - Craig-Hallu ...